Data from the APHINITY, Adjuvant Pertuzumab and Herceptin IN Initial TherapY in Breast Cancer, trial includes 4,805 patients with histologically confirmed Her2 +ve early BCA treated with standard adjuvant CT and trastuzumab plus either pertuzumab or placebo for 1 year (85, 86). This evidence concerns the gene ERBB2 and breast cancer.